A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Clinical trial NCT07063745 · RECRUITING

Trial details

NCT number: NCT07063745
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Start date: 2026-01-02
Primary completion: 2031-08-12
Enrollment: 590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.